Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tilmann Bochtler

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Haematologica|May 28, 2017
Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemiaWenwen Wang, Thomas Stiehl, Simon Raffel, et al.
Blood|January 26, 2017
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemiaTilmann Bochtler, Martin Granzow, Friedrich Stölzel, et al.
Blood|March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationJan M Middeke, Min Fang, Jan J Cornelissen, et al.
Nature Communications|October 24, 2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trialMaria Pouyiourou, Bianca N Kraft, Timothy Wohlfromm, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
International Journal of Cancer|April 20, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II TrialBenedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITDAnthony D Ho, Johannes Schetelig, Tilmann Bochtler, et al.
Lancet (London, England)|August 3, 2024
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 studyAlwin Krämer, Tilmann Bochtler, Chantal Pauli, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2021
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical fieldAnna-Lena Volckmar, Petros Christopoulos, Martina Kirchner, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Haematologica|May 28, 2017
Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemiaWenwen Wang, Thomas Stiehl, Simon Raffel, et al.
Blood|January 26, 2017
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemiaTilmann Bochtler, Martin Granzow, Friedrich Stölzel, et al.
Blood|March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationJan M Middeke, Min Fang, Jan J Cornelissen, et al.
Nature Communications|October 24, 2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trialMaria Pouyiourou, Bianca N Kraft, Timothy Wohlfromm, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
International Journal of Cancer|April 20, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II TrialBenedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITDAnthony D Ho, Johannes Schetelig, Tilmann Bochtler, et al.
Lancet (London, England)|August 3, 2024
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 studyAlwin Krämer, Tilmann Bochtler, Chantal Pauli, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2021
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical fieldAnna-Lena Volckmar, Petros Christopoulos, Martina Kirchner, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Pageof 6